Taipei Exchange - Delayed Quote TWD

Feature Integration Technology Inc. (4951.TWO)

66.70

-1.50

(-2.20%)

At close: 1:30:08 PM GMT+8

Top plays among the 'Magnificent 7' and Big Tech stocks as Trump returns to the White House

Magnificent 7 stocks may be poised for gains as President-elect Donald Trump returns to the White House.

Yahoo Finance 22 hours ago

NVDA

XLK

TSLA
Here’re Infuse Asset Management’s Views on Tesla (TSLA)

Infuse Asset Management, an investment management company, released its fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The goal of Infuse is to become the best-performing public equity fund over the next 50 years. After operating for just over two years, it was a slow beginning to the process […]

Insider Monkey 4 minutes ago

TSLA
Tesla Stock Had a Huge 2024 but EV Start-Ups Rivian and Lucid Stocks Plunged. What That Could Mean for 2025

Risk-averse investors probably wouldn't have enjoyed holding Tesla (NASDAQ: TSLA) stock last year. Halfway through the year, Tesla shares were down by over 20% even as the S&P 500 index had marched 15% higher. Shares of fellow electric vehicle (EV) makers Rivian Automotive (NASDAQ: RIVN) and Lucid Group (NASDAQ: LCID) also had a tough start to 2024.

Motley Fool 6 minutes ago

TSLA

RIVN
Moderna surprises the Street by predicting a bigger-than-expected sales drop

Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 billion and $2.5 billion after hitting as much as $3.1 billion last year. Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales.

Associated Press Finance 13 minutes ago

MRNA
Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies

Johnson & Johnson (JNJ) on Monday agreed to acquire Intra-Cellular Therapies (ITCI) for about $14.6

PREMIUM
MT Newswires 20 minutes ago

JNJ

ITCI
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal

Johnson & Johnson kicked off the J.P. Morgan Healthcare Conference on Monday with the $14.6 billion acquisition of Intra-Cellular Therapies.

Investor's Business Daily 21 minutes ago

JNJ

ITCI
Apple Falls to Second Place Globally as Samsung's S24 Dominates Smartphone Market

Apple's global smartphone market share dips; Samsung leads, buoyed by S24 demand and A-series success

GuruFocus.com 55 minutes ago

AAPL

SSNLF
Tesla CEO Elon Musk diverts Cybertruck deliveries to help in L.A. fire amid political feuding

Tesla CEO Elon Musk, who serves as a key ally to President-elect Donald Trump, was also accused of spreading fire disinformation by California Gov. Gavin Newsom and others on the X platform.

Automotive News 1 hour ago

TSLA
Abercrombie Had a Strong Holiday. Why the Stock Is Falling.

The retailer now sees net sales increasing between 7% and 8% from last year after a record holiday season.

Barrons.com 1 hour ago

ANF
U.S. Steel Stock Jumps as US Extends Deadline for Nippon Steel to Axe Takeover

U.S. Steel shares are jumping in premarket trading Monday after the U.S. government extended until June from next month a deadline for Nippon Steel to abandon its planned $14.1 billion acquisition of the American steelmaker.

Investopedia 1 hour ago

X
Lululemon Hikes Q4 Earnings, Revenue Guidance. LULU Stock Pops.

Lululemon stock jumped early Monday after the athleisure retailer guided higher on fourth-quarter earnings and sales based on its strong holiday performance. Lululemon also expects its gross margin to increase about 30 basis points from last year. It previously guided a decrease of 20 to 30 basis points.

Investor's Business Daily 1 hour ago

LULU
Moderna 2025 Revenue Guidance Below Wall Street’s Estimates

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street expectations of $2.9 billion.

The Wall Street Journal 1 hour ago

JPM

MRNA
Exclusive-Tech supplier Arm plans to hike prices, has considered developing its own chips

Arm Holdings, a technology supplier to chip firms, is developing a long-term strategy to hike prices by as much as 300% and has discussed designing its own chips in a move to compete with its biggest customers. For decades, the British firm kept a low profile while operating at the heart of billions of dollars of chip sales per year. It licenses the intellectual property that Apple, Qualcomm, Microsoft and others use to design their chips, charging a small royalty for each chip produced with Arm technology.

Reuters 1 hour ago

QCOM

AAPL

ARM
Lululemon Stock Rises on Boost to Earnings and Revenue Guidance

FEATURE Lululemon Athletica stock climbed in premarket trading Monday after the athletic apparel company raised its earnings and revenue guidance for the fourth quarter. Lululemon said it anticipates net revenue in the range of $3.

Barrons.com 1 hour ago

LULU
Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Decoy’s proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE

GlobeNewswire 1 hour ago

SLRX
Gorilla Addresses Market Misinformation and Announces Increase to Share Buyback Programme

London, United Kingdom--(Newsfile Corp. - January 13, 2025) - Gorilla Technology Group Inc. (NASDAQ: GRRR) ("Gorilla" or the "Company") CEO Jay Chandan responded to recent market concerns raised by shareholders following the stock's recent fluctuation and reiterated the Company's strong financial position and strategic priorities. The Company remains focused on delivering sustainable growth, building its robust pipeline and creating long-term value for shareholders.A Message to Our Valued Invest

Newsfile 1 hour ago

GRRR

GRRRW
5 Things to Know Before the Stock Market Opens

News of the day for Jan. 13, 2025

Investopedia 1 hour ago

AAPL
Lululemon Raises 4Q Revenue, Profit Targets

Lululemon athletica said it now expects revenue and profit to be higher than previously thought for the fourth quarter as shoppers flocked to its stores over the Christmas and holiday period.

The Wall Street Journal 1 hour ago

LULU
Apple Stock Slips. Here’s How Much iPhone Sales Dropped Last Year.

The company's smartphone sales fell in 2024 amid a muted response to its artificial-intelligence features, according to Counterpoint Research.

Barrons.com 1 hour ago

AAPL
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancersCayman Islands, January 13, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it will be presenting a poster at the 2025 ASCO Gastrointestinal (GI) Cancers Symposium taking place January 23-25, 2025, in San Francisco, Californ

GlobeNewswire 1 hour ago

SLXN

SLXNW

Performance Overview

Return	4951.TWO	TSEC CAPITALIZATION WEIGHTED ST
YTD	+1.21%	-3.03%
1-Year	+0.22%	+28.41%
3-Year	+13.02%	+22.38%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Feature Integration Technology Inc. (4951.TWO)

Related News

Top plays among the 'Magnificent 7' and Big Tech stocks as Trump returns to the White House

Here’re Infuse Asset Management’s Views on Tesla (TSLA)

Tesla Stock Had a Huge 2024 but EV Start-Ups Rivian and Lucid Stocks Plunged. What That Could Mean for 2025

Moderna surprises the Street by predicting a bigger-than-expected sales drop

Johnson & Johnson Strikes $14.6 Billion Deal to Acquire Intra-Cellular Therapies

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal

Apple Falls to Second Place Globally as Samsung's S24 Dominates Smartphone Market

Tesla CEO Elon Musk diverts Cybertruck deliveries to help in L.A. fire amid political feuding

Abercrombie Had a Strong Holiday. Why the Stock Is Falling.

U.S. Steel Stock Jumps as US Extends Deadline for Nippon Steel to Axe Takeover

Lululemon Hikes Q4 Earnings, Revenue Guidance. LULU Stock Pops.

Moderna 2025 Revenue Guidance Below Wall Street’s Estimates

Exclusive-Tech supplier Arm plans to hike prices, has considered developing its own chips

Lululemon Stock Rises on Boost to Earnings and Revenue Guidance

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Gorilla Addresses Market Misinformation and Announces Increase to Share Buyback Programme

5 Things to Know Before the Stock Market Opens

Lululemon Raises 4Q Revenue, Profit Targets

Apple Stock Slips. Here’s How Much iPhone Sales Dropped Last Year.

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Performance Overview